 CAMBRIDGE, Mass., Sept. 16, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leaps anti-Dickkopf-1 DKK1 antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd. 